家族性肥厚型心肌病心脏型肌球蛋白结合蛋白C基因c.G772A突变研究

摘要
图/表
参考文献(20)
相关文章 (0)

全文: PDF (527 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究中国人家族性肥厚型心肌病（HCM）的致病基因，分析基因型与临床表型的关系。方法以2016年青岛市第三人民医院心内科1例住院患者为先证者的HCM家系，在此HCM家系中进行了包括心脏型肌球蛋白结合蛋白C（MYBPC3）在内的30个HCM相关的致病基因的编码区及侧翼区进行了检测，利用靶向外显子捕获测序的方法对HCM先证者的30个与遗传性心肌病相关的基因进行全外显子扩增和高通量测序，进一步通过Sanger测序法在家系内及200名健康志愿者中进行验证。家系调查资料包括临床表现、体格检查、心电图及超声心动图。结果该家系共6人，有血缘关系的4例研究对象中，3例携带MYBPC3基因c.G772A杂合错义突变，该突变位点位于MYBPC3基因第6号外显子上，并使258位的谷氨酸（E）变为赖氨酸（K），该家系先证者携带MYBPC3突变，中年发病，临床表型温和，超声示室间隔明显增厚（厚度为18.3 mm）。结论 MYBPC3基因c.G772A杂合错义突变可能是该HCM家系的致病突变，其携带者临床表型温和，有的无临床表现，提示其他因素如其他基因、年龄、环境等因素参与了HCM的发展过程。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘杰▲ 刘福颂▲ 王芳邢晓博樊光红朱玉召张克传孙芳芳

关键词 ：肌球蛋白结合蛋白C, 肥厚型心肌病, 突变

Abstract：Objective To study the pathogenic gene of Chinese familial hypertrophic cardiomyopathy (HCM), and to analyze the relationship between genotype and clinical phenotype. Methods One inpatient treated in Department of Cardiology, the Third People′s Hospital of Qingdao in 2016 was taken as the HCM family of proband, in which, the coding region and flanking region of 30 virulence gene related to HCM including cardiac myosin binding protein C (MYBPC3) were detected, and the 30 genes related to hereditary cardiomyopathy of HCM proband were identified by whole exons amplification and high-throughput sequencing through targeted exon trapping sequencing, and the identified mutation was further detected through bi-directional Sanger sequencing in the family members and 200 healthy volunteers. Pedigree analysis included clinical manifestation, physical examination, ECG and echocardiogram. Results Among 4 blood-related members in the six members of family, 3 members had MYBPC3 gene c.G772A hybrid missense mutation. The mutation was existed in the 6th exon of MYBPC3 gene, which made a 258-bit glutamic acid (E) into a lysine (K). The proband of the family carried on MYBPC3 mutation, who was attacked in the middle-age, clinical phenotype was mild, and the ultrasound showed that the interventricular septum was significantly thickened (the thickness was 18.3 mm). Conclusion MYBPC3 gene c.G772A hybrid missense mutation may be the pathogenic mutations of this HCM family. Some carriers have mild clinical phenotype, and some have no clinical manifestation, which suggests that other factors such as other genes, age, environment also participate in the development process of HCM.

Key words： Cardiac myosin binding protein-C Hypertrophic cardiomyopathy Mutation

引用本文:

刘杰*▲ 刘福颂*▲ 王芳邢晓博樊光红朱玉召张克传孙芳芳. 家族性肥厚型心肌病心脏型肌球蛋白结合蛋白C基因c.G772A突变研究[J]. 中国医药导报, 2017, 14(29): 65-68.
LIU Jie*▲ LIU Fusong*▲ WANG Fang XING Xiaobo FAN Guanghong ZHU Yuzhao ZHANG Kechuan SUN Fangfang. Research on the mutation of cardiac myosin binding protein C gene c.G772A in familial hypertrophic cardiomyopathy. 中国医药导报, 2017, 14(29): 65-68.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I29/65

[1] Stroumpoulis KI，Pantazopoulos IN，Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death [J]. World J Cardiol，2010，2（9）：289-298.
[2] Maron BJ，Haas TS，Ahluwalia A，et al. Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes：From the United States National Registry [J]. Am J Med，2016，129（11）：1170-1177.
[3] Sen-Chowdhry S，Jacoby D，Moon JC，et al. Update on hypertrophic cardiomyopathy and a guide to the guidelines [J]. Nat Rev Cardiol，2016，13（11）：651-675.
[4] Carrier L，Mearini G，Stathopoulou K，et al. Cardiac myosin-binding protein C（MYBPC3）in cardiac pathophysiology [J]. Gene，2015，573（2）：188-197.
[5] Mohamed IA，Krishnamoorthy NT，Nasrallah GK，et al. The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy- Progress and Novel Therapeutic Opportunities [J]. J Cell Physiol，2017，232（7）：1650-1659.
[6] Gersh BJ，Maron BJ，Bonow RO，et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol，2011， 58（25）：e212-e260.
[7] Elliott PM，Anastasakis A，Borger MA，et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy：the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology（ESC）[J]. Eur Heart J，2014，35（39）：2733-2779.
[8] Maron BJ，Casey SA，Hauser RG，et al. Clinical course of hypertrophic cardiomyopathy with survival to advanced age [J]. J Am Coll Cardiol，2003，42（5）：882-888.
[9] Flashman E，Redwood C，Moolman-Smook J，et al. Cardiac myosin binding protein C：its role in physiology and disease [J]. Circ Res，2004，94（10）：1279-1289.
[10] Yamamoto K，Moos C. The C-proteins of rabbit red，white，and cardiac muscles [J]. J BiolChem，1983，258（13）：8395-8401.
[11] Vaughan KT，Weber FE，Einheber S，et al. Molecular cloning of chicken myosin-binding protein（MyBP）H（85-kDa protein）reveals extensive homology with MyBP-C（C-protein）with conserved immunoglobulin C2 and fibronectin type Ⅲ motifs [J]. J BiolChem，1993，268（5）：3670-3676.
[12] Gilbert R，Kelly MG，Mikawa T，et al. The carboxyl terminus of myosin binding protein C（MyBP-C，C-protein）specifies incorporation into the A-band of striated muscle [J]. J Cell Sci，1996，109（Pt 1）：101-111.
[13] Weisberg A，Winegrad S. Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle [J]. Proc Natl Acad Sci U S A，1996， 93（17）：8999-9003.
[14] Hartzell HC. Effects of phosphorylated and unphosphorylated C-protein on cardiac actomyosin ATPase [J]. J MolBiol，1985，186（1）：185-195.
[15] De Lange WJ，Grimes AC，Hegge LF. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction [J]. J Gen Physiol，2013，142（3）：241-255.
[16] Niimura H，Bachinski LL，Sangwatanaroj S，et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy [J]. N Engl J Med，1998，338（18）：1248-1257.
[17] Song L，Zou Y，Wang J，et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy [J]. Clin Chim Acta，2005，351（1/2）：209-216.
[18] Page SP，Kounas S，Syrris P，et al. Cardiac myosin binding protein-C mutations in families withhypertrophic cardiomyopathy：disease expression in relation to age，gender，and long term outcome [J]. Circ Cardiovasc Genet，2012，5（2）：156-166.
[19] Marston S，Copeland O，Jacques A，et al. Evidence from human myectomy samples that MYBPC3mutations cause hypertrophic cardiomyopathy through haploinsufficiency [J]. Circ Res，2009，105（3）：219-222.
[20] Cecconi M，Parodi MI，Formisano F，et al. Targeted next-generation sequencing helps to decipher the genetic and phenotypic heterogeneity of hypertrophic cardiomyopathy [J]. Int J Mol Med，2016，38（4）：1111-1124.